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PIH62
MeasurIng sPendIng Trends For THose WITH eMPloyer-sPonsored 
Insurance usIng adMInIsTraTIve daTa
Marder WD1, Moldwin E2, Pickens GT2
1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Chicago, MA, USA
Objectives: There is limited timely information about healthcare spending in 
the US for those people under 65 with employer-sponsored insurance. This study 
explores the methods needed to use a large administrative database to fill this 
need. The fully implemented methodology will be used to portray recent trends 
in overall spending and highlight the role of prescription drugs in the context of 
those trends. MethOds: The Truven Health MarketScan database is updated each 
calendar quarter. This convenience sample is weighted to reflect the age, sex, and 
location characteristics of the US population with employer-sponsored insurance 
as captured by the US Medical Expenditure Panel Survey. Recent quarterly spending 
is adjusted for incurred but not yet reported services using a combination of cor-
rection factors and time series analysis. Spending is classified either by setting or 
by provider type. Overall and subpopulation breakdowns are presented. Results: 
Per capita annual spending has seen a compound annual growth rate of 5.2% over 
the period of 2003–2013. While the 0–17 age group has seen the highest annual 
growth rate at 6.5% (from $1,476 in 2003 to $2,772 in 2013), the 45–64 age group 
continues to have a higher level of expenditure ($8,175) despite a lower annual 
growth rate of 4.1%. Outpatient spending grew faster (6.0%) than either inpatient 
(4.5%) or prescription drug (4.0%). In the most recent year there has been an uptick 
in prescription drug spending fueled almost entirely by new treatments for Hepatitis 
C. cOnclusiOns: It is possible to create a useful, timely index of spending for 
the under 65 population of the US with employer-sponsored insurance. Recent 
trends indicate a growth in spending for children and a recently revived growth 
for prescription drugs.
PIH63
TeMPoral Trend In use oF PerManenT FeMale sTerIlIzaTIon 
Procedures and cHaracTerIsTIcs oF WoMen WHo undergo THeM In a 
coMMercIally-Insured PoPulaTIon In THe u.s
Carney P1, Lin J2, Xia F3, Law A1
1Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA, 2Novosys Health, Green Brook, NJ, USA, 
3Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA
Objectives: Literature is lacking on the temporal pattern of use of permanent steri-
lization procedures and the characteristics of women who undergo them. This study 
evaluated the temporal pattern of use of hysteroscopic sterilization (HS) vs. inter-
val laparoscopic bilateral tubal ligation (LBTL) and differences in characteristics of 
women who undergo permanent sterilization procedures. MethOds: Women aged 
15-49 years who had a claim for HS or LBTL procedures during 1/1/2003-12/31/2012 
were identified from the Truven Health MarketScan Commercial Claims and 
Encounters database. The proportions and characteristics of women who underwent 
HS and LBTL were determined for the study population and subgroups stratified 
by year of procedure. Logistic regressions were used to identify predictors of use of 
HS vs. LBTL. Results: Among the study population, 32,012 had HS and 64,725 had 
LBTL. Women who had HS vs. LBTL were slightly older (37.2 vs. 36.4 years, p< 0.0001), 
but had similar Charlson Comorbidity Index scores. The proportion of women who 
had HS increased from 7% in 2005 to 45% in 2012. Compared to women who had 
a sterilization procedure between 2003 and 2007, women who had one between 
2008 and 2012 were more likely to undergo HS (Odds Ratio (OR): 7.1, p< 0.0001). 
Obesity was associated with a greater likelihood of having HS vs. LBTL (OR: 1.08, 
p= 0.03). Additionally, slightly greater age (OR: 1.03, p< 0.0001), having had a prior 
pregnancy/delivery (OR: 1.38, p< 0.0001), and having had prior oral contraceptive use 
(OR: 1.53, p< 0.0001) were associated with greater likelihoods of having had HS than 
LBTL. cOnclusiOns: Using a large claims database analysis, we observed among 
commercially-insured women that the likelihood of having HS vs. LBTL increased 
approximately 7-fold in years 2008-2012 from in years 2003-2007. Older age, prior 
pregnancy/delivery, and prior oral contraceptive use were associated with a greater 
likelihood of having HS vs. LBTL.
PIH64
gender dIsParITIes In MIgraIne PHarMacoTHeraPy: aPPlIcaTIon oF 
ProPensITy score-MaTcHed analyses
Lai L1, Sanabria S2
1Nova Southeastern University, Davie, FL, USA, 2Nova Southeastern University, Ft. Lauderdale, 
FL, USA
Objectives: Migraine is a debilitating chronic disease that affects approximately 
13% of the United States population. Gender differences in migraine treatment have 
been studied; however, the results are often overlooked due to lack of controlling 
for selection bias. The study aimed to investigate gender differences in migraine 
treatment, using propensity score-matched analyses. MethOds: A retrospective 
population-based study was conducted by analyzing a national database from 2010 
National Ambulatory Medical Care Survey. All patient visits with a diagnosis of 
migraine were included. A series of weighted descriptive analyses were used to 
estimate the prevalence of medications recommended in the American Neurology 
Association practice guidelines. Multivariate logistic regression and Greedy 8 to 1 
digit match were used to create propensity scores. A propensity score weighted 
logistic regression model was fitted to compare the gender difference on migraine 
treatment while controlling for age, race, pay type, and physician specialty. All analy-
ses utilized SAS PROCSURVEY applications and incorporated sample weights and 
standard errors. Results: Among 5.45 million outpatient visits that took place in 
2010 with migraine diagnosis, female accounted for nearly four-times than male 
(79.8% vs. 20.2%). Of these, 3.08 million visits (56.48%) received at least one abortive 
or prophylactic migraine prescription. Prior to propensity-score matching, the socio-
economic characteristics of the two cohorts (with vs. without migraine pharmaco-
therapy) were significantly different (P< 0.001). After matching, there was no longer 
a significant difference between two cohorts (P> 0.05). Female received significant 
more migraine treatment than male (OR: 3.2, 95% CI: 1.137-8.932). cOnclusiOns: 
The assessment of gender differences in health care is challenging because of the 
potential biases that require careful adjustment. This study successfully reduced 
selection bias by propensity score-matched methodology and concluded significant 
gender disparity in migraine pharmacotherapy. This study also provides an empiri-
cal evident of undertreated migraine conditions in the US.
PIH65
TreaTMenT PaTTerns oF WoMen dIagnosed WITH uTerIne FIbroIds 5 
years Pre and PosT dIagnosIs: a longITudInal reTrosPecTIve claIMs 
analysIs oF a coMMercIally Insured PoPulaTIon In THe us
Soliman AM1, Fuldeore M1, Yang H2, Du EX2, Wu EQ2, Winkel C3
1AbbVie Inc., North Chicago, IL, USA, 2Analysis Group, Inc., Boston, MA, USA, 3Georgetown 
University School of Medicine, Washington, DC, USA
Objectives: To evaluate treatment patterns among women with uterine fibroid (UF) 
versus matched controls for 5 years before and after diagnosis. MethOds: Women 
with a UF diagnosis (International Classification of Diseases 218.xx) aged 18-45 years 
were identified in Truven Health MarketScan® 2000-2010 data, and matched 1:1 to 
women without UF (control) by age, region, and insurance type. The first recorded 
UF diagnosis date was assigned as the index date for the UF patient and matched 
control. Continuous eligibility in a health plan for ≥ 1 year pre- and post-index was 
required. UF-related medications and surgical treatments during the five pre- and 
post-index years were evaluated annually, and compared between UF patients and 
controls using McNemar’s tests. Results: A total of 84,954 matched pairs, with a 
mean age of 39.3 years at the index date were included in the analysis. During the 
3 years prior to the index date, annual medication use (ranging from 18.7-19.5% 
vs. 16.5-18.4% for combined oral contraceptives and 0.4-0.9% vs. 0.2-0.3% for GnRH 
agonists) and UF-related surgery use (0.8-0.9% vs. 0.1-0.4% for endometrial abla-
tions), respectively, was significantly higher among UF patients than controls (all p 
values < 0.05). In the first year post-index, a greater proportion of UF patients than 
controls were treated with medications (combined oral contraceptives, 17.1% vs. 
15.6%; progestins, 10.7% vs. 4.9%; and GnRH agonists, 2.8% vs. 0.2%) and surgeries 
(hysterectomies, 27.9% vs. 0.5%; endometrial ablations, 6.3% vs. 0.6%; myomecto-
mies, 5.9% vs. < < 0.1%), respectively (all p values < 0.05). In the next four years of 
follow-up, the annual utilization difference decreased, but remained higher in UF 
patients and the differences were significant for GnRH agonist, hysterectomy, and 
myomectomy use. cOnclusiOns: Patients with UF used significantly more UF 
treatments than controls after diagnosis, and also during the period before diag-
nosis. Treatment usage peaked in the first year post-diagnosis.
MenTal HealTH – clinical outcomes studies
PMH1
HealTHcare uTIlIzaTIon and cosTs oF seroTonIn syndroMe WITH 
concoMITanT use oF seroTonergIc agenTs
Xie L.1, Wang Z.2, Alley S.3, Baser O.4, Nguyen C.5
1STATinMED Research, Ann Arbor, MI, USA, 2Eisai Inc., Woodcliff Lake, NJ, USA, 3Long Beach VA 
Healthcare System, Southern California Institute of Research, Long Beach, CA, USA, 4STATinMED 
Research, The University of Michigan, MEF University, Ann Arbor, MI, USA, 5Long Beach VA 
Healthcare System, University of California Irvine School of Medicine, Irvine, CA, USA
Objectives: Serotonin syndrome (SS) is an adverse drug reaction that may occur 
in patients receiving monotherapy or combinations of serotonergic agents (SAs). 
This study examined healthcare utilization and costs of SS in two different popu-
lations. MethOds: Adult (age ≥ 18 years) patients prescribed SAs were identified 
using the Veterans Health Administration (VHA) dataset (01OCT2008-30SEPT2012) and 
the IMS PharMetrics Plus dataset (01JAN2010-31DEC2013). Patients with continuous 
health plan enrollment 12 months pre-index date, defined as the first SA prescrip-
tion claim date, were included and observed until death, disenrollment or the end of 
the study period. Patients were assigned to cohorts based on drug exposure: single 
monoamine oxidase inhibitor (MAOI) drug, MAOI drugs in combination with other 
SAs, single non-MAOI SA, and multiple non-MAOI SAs (2, 3, 4, and ≥ 5 SAs). Outcomes 
of interest were annual incidences of SS event (ICD-9-CM: 333.99) and associated 
health care utilization and costs. Results: The incidence rate of SS was similar 
between veterans (VHA) and commercially insured patients (IMS) prescribed SAs and 
decreased over time (IMS: 0.17% in 2010 to 0.09% in 2013; VHA: 0.19% in 2009 to 0.07% 
in 2012). 0.88% and 4.35% of all SS events led to hospitalization in the IMS and VHA 
populations, respectively. Proportion of IMS patients with SS-related hospitalization 
increased as the number of non-MAOI SAs increased (0.24% for one drug vs. 6.93% for 
≥ 5 drugs). Average healthcare cost per SS event was higher in the MAOI combination 
cohort (IMS: $2,474; VHA: $2,896) and the ≥ 5 non-MAOI SAs cohort (IMS: $1,167; VHA: 
$3,837) than the single non-MAOI SA cohort. cOnclusiOns: The overall incidence 
of SS and proportion of serious SS leading to hospitalization are similar in the VHA 
and IMS populations. Use of MAOIs or multiple SAs concomitantly increases the risk 
of SS and leads to higher health care utilization and costs.
PMH2
anTIcHolInergIc MedIcaTIon use and rIsk oF IncIdenT FracTures In 
THe elderly WITH dePressIon
Chatterjee S.1, Aparasu R.1, Carnahan R.2, Chen H.1, Johnson M.L.1
1University of Houston, Houston, TX, USA, 2University of Iowa College of Public Health,, Iowa, 
IA, USA
Objectives: There is limited evidence regarding the role of anticholinergic medica-
tions in falls/fractures among the elderly. This study examined the risk of fractures 
associated with anticholinergic use in elderly nursing home residents with depres-
sion. MethOds: A population-based nested case control study was conducted 
using 2007-2010 Minimum Data Set (MDS)-linked Medicare data from all states. 
Patients with continuous coverage in Medicare Parts A, B, D and no HMO coverage 
during the study period or until death were considered. The base cohort included 
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Medicare beneficiaries aged ≥ 65 years, diagnosed with depression, and no history of 
falls/fractures in 2007 (Baseline Period). Cases were identified as patients with inci-
dent fractures following the baseline period. For each case, 4 age and sex-matched 
controls were selected using incidence density sampling. The primary outcome 
was an inpatient or outpatient claim for fractures, between January 1, 2008 and 
December 31, 2010. Anticholinergic exposure was defined using Anticholinergic 
Drug Scale (ADS). Prescription of level 2/3 anticholinergic medications 30 days pre-
ceding the event date formed the primary exposure. Conditional logistic regression 
model stratified on matched case-control sets was performed to assess the fracture 
risk, after controlling for other risk factors of the outcome. Results: The study 
sample included 43,402 cases of fractures and 173,608 matched controls (Incidence 
Density 1:4). After adjusting for other risk factors, there was no difference in risk 
with high-level anticholinergic use compared to non-use (Relative Risk, RR 1.02; 95% 
Confidence Interval [CI], 1.00-1.04). The findings remained consistent across levels 
of anticholinergic potency (Level 2, RR 1.01, 95% CI, 0.98-1.06; Level 3, 95% CI, 1.03, 
0.99-1.07). cOnclusiOns: Use of anticholinergic medications was not associated 
with a higher risk of fractures compared to no use among elderly residents with 
depression. Given their safety concerns, there is a need to further evaluate other 
adverse outcomes associated with anticholinergics in the elderly.
PMH3
THe IMPacT oF alTernaTIve anTIPsycHoTIc MedIcaTIons on THe rIsk oF 
adverse evenTs In PaTIenTs TreaTed For scHIzoPHrenIa
Jiang Y., Park S., McCombs J.
University of Southern California, Los Angeles, CA, USA
Objectives: This study compares the risks of side effects [SE] associated with a 
broad of range of typical and atypical antipsychotics used to treat patients with 
schizophrenia. MethOds: Medical and pharmacy claims data from Humana from 
January 2007 to June 2013 were used to define episodes of antipsychotic drug therapy 
for patients with schizophrenia. Episodes were screened for a minimum of 180 days 
of pre-episode and 360 days of post-episode data, and for the existence of study SEs 
prior to the episode index date. Study samples ranged from N= 97,481 for rhabdomy-
olysis (RM) to N= 99,017 acute urinary retention (AUR). Other SE for analysis included 
acute kidney injury (AKI), hypotension, pneumonia (PNA), acute coronary syndrome 
(ACS) or ischemic stroke/cerebral infarction, and ventricular cardiac arrhythmia 
(VCA). Logistic regression models were used to estimate the impact of alternative 
antipsychotics on the risk of an emergent SE in the year following the initiation 
of treatment. The logistic models controlled for patient demographics, treatment 
history, concomitant use of antidepressants, mood stabilizers and anticonvulsants, 
and diagnostic and drug use profiles in the prior 6 months. Haloperidol was used as 
the comparison drug. Results: Perphenazine and ziprasidone reduced the risk of 
acute cardiovascular events relative to haloperidol. The risk of acute kidney injury 
was significantly increased in patients taking aripiprazole, olanzapine, quetiapine, 
risperidone and ziprasidone relative to haloperidol. The risk of hypotension was 
elevated in chlorpromazine and quetiapine patients and reduced in those using pali-
peridone, perphenazine and thiothixene. The risk of AUR was increased in patients 
using fluphenazine, but reduced in patients using aripiprazole, risperidone and 
thiothixene. The risk of RM was increased by the use of fluphenazine and quetia-
pine while the risk of pneumonia was elevated for patients using chlorpromazine, 
clozapine, paliperidone and quetiapine. cOnclusiOns: The risk of side effects 
varies widely across antipsychotic medications.
PMH4
THe IMPacT oF alTernaTIve anTIPsyconTIc MedIcaTIons on THe rIsk oF 
adverse evenTs In PaTIenTs TreaTed For bIPolar dIsorders
Jiang Y., Park S., McCombs J.
University of Southern California, Los Angeles, CA, USA
Objectives: This study compares the risks of side effects [SE] associated with a broad 
of range of atypical and typical antipsychotics used to treatment patients with bipolar 
disorder. MethOds: Medical and pharmacy claims data from Humana from January 
2007 to June 2013 were used to define episodes of antipsychotic drug therapy for 
patients with bipolar disorder. Episodes were screened for a minimum of 180 days of 
pre-episode and 360 days of post-episode data, and for the existence of study SEs prior 
to the episode index date. Study samples ranged from N= 147,658 for rhabdomyolysis 
[RM] to N= 150,084 acute urinary retention [AUR]. Other SE for analysis included acute 
kidney injury [AKI], hypotension, pneumonia (PNA), acute coronary syndrome (ACS) 
or ischemic stroke/cerebral infarction, ventricular (tachy) arrhythmia (VCA). Logistic 
regression models were used to estimate the impact of alternative antipsychotics on 
the risk of an emergent SE in the year following the initiation of treatment. The logistic 
models controlled for patient demographics, treatment history, concomitant use of 
antidepressants, mood stabilizers and anticonvulsants, diagnostic and drug use pro-
files in the prior 6 months. Haloperidol was used as the comparison drug. Results: 
Aripiprazole, ziprasidone and risperidone did not differentiate relative to haliperidol. 
Only fluphenazine increases the risk of cardiovascular events relative to heliperidol. 
All other SE impacts related to specific antipsychotics were related to kidney disorders 
or pneumonia. Chlorpromazine increased the risk of acute kidney injury, hypoten-
sion, rhabdomyolysis and pneumonia. Clozapine increased the risk of pneumonia. 
Olanzapine increased the risk of AKI and pneumonia but significantly decreased the 
risk of AUR. Paliparidone also increased the risk of PNA and decreased the risk of 
AUR. Quetiapine increased the risk of AKI while perphenazine decreased the risk of 
hypotension and thiothixene decreased the risk of AUR. cOnclusiOns: The risk of 
side effects varies widely across antipsychotic medications.
PMH5
a reTrosPecTIve coHorT sTudy usIng claIMs daTabase To InvesTIgaTe 
THe acTual sITuaTIon In TreaTMenT oF PanIc dIsorder In JaPan
Asami Y.1, Kuribayashi K.1, Hoshino Y.1, Yamamoto Y.2, Nagayasu S.2, Yamazaki T.2,  
Fujimoto Y.3
1Pfizer Japan Inc., Tokyo, Japan, 2MinaCare Co. Ltd, Tokyo, Japan, 3Pfizer Japan Inc, Tokyo, Japan
Objectives: The epidemiological evidence of panic disorder (PD) is limited and 
little is known about the treatment for PD in the real clinical setting. The aim of 
this study was to determine the prevalence of PD, and to investigate concurrent 
diseases and prescriptions in patients with PD using a Japanese healthcare insur-
ance claims database. MethOds: This was a retrospective cohort study in patients 
having at least one diagnosis record of PD (ICD-10 code: F41.0), extracted from the 
MinaCare claims database (MinaCare Co. Ltd, Japan). The annual prevalence was 
estimated based on claims of fiscal years of 2011 and 2012 (Apr to Mar). The study 
cohort to investigate concurrent diseases and prescribed drugs consists of newly 
diagnosed patients, which was defined as patients with no diagnosis record of PD 
within 6 months prior to the 1st diagnosis of PD in the database. Results: The 
estimated annual prevalence of PD was approximately 0.3%. Higher prevalence was 
observed in females in their 20s, 30s and 40s. In 2,100 newly diagnosed PD patients, 
the common diseases recorded concurrently at 1st PD diagnosis were insomnia, 
depression and neurosis. The predominant drugs prescribed at 1st PD diagnosis 
were SSRIs and benzodiazepines, as recommended in the current guideline as 1st 
line treatment; however, the proportion of patients prescribed both SSRIs together 
with benzodiazepines was less than 40%, and almost half of the patients were not 
prescribed SSRIs at 1st PD diagnosis. This prescription trend showed no remarkable 
change during the 6 months post-diagnosis period. cOnclusiOns: The estimated 
prevalence including gender difference and age distribution were consistent with 
previous studies of PD. However, the prescription at 1st PD diagnosis suggests the 
existence of a gap between the real-world practices and the guideline recommen-
dation. Further investigation is needed to identify possible factors having impact 
on adequate treatment of PD.
PMH6
dePressIon TreaTMenT PaTTerns aMong IndIvIduals WITH cHronIc 
obsTrucTIve PulMonary dIsease
Deb A., Sambamoorthi U.
West Virginia University, Morgantown, WV, USA
Objectives: The prevalence of co-occurring depression in chronic obstructive 
pulmonary disease (COPD) is as high as 40% and associated with substantial nega-
tive outcomes. Prior studies have shown that combined treatment with psycho-
therapy and antidepressants is superior to antidepressant treatment alone in 
reducing depressive symptoms and improving quality of life. However, popula-
tion based studies on the patterns of depression treatment among individuals 
with co-occurring COPD and depression are limited. We examined the patterns 
of depression treatment in various subgroups of individuals with co-occurring 
COPD and depression. MethOds: We used a retrospective, cross-sectional study 
design, pooling data from the 2009 and 2011 Medical Expenditure Panel Survey 
(MEPS). The analytical sample consisted of 886 individuals aged 21 years or older, 
diagnosed with COPD and depression. We classified depression treatment into 
three mutually exclusive categories: no depression treatment; antidepressants 
use only; and psychotherapy in conjunction with antidepressants. We conducted 
chi-squared tests and multinomial logistic regressions to examine patterns of 
depression treatment by socio-demographic, medical conditions and health status 
characteristics of this population. Results: Overall, 18.5% of the study population 
reported no treatment for depression, 72% reported antidepressants use only and 
only 9.5% reported the use of psychotherapy in conjunction with antidepressants. 
Females were significantly more likely than males to receive psychotherapy and 
antidepressants for depression treatment (AOR= 2.41, 95% CI= 1.21, 4.81). Uninsured 
individuals were less likely than individuals with private insurance in receiv-
ing combined treatment (AOR= 0.25, 95% CI= 0.08, 0.84). Individuals with fair/poor 
perceived mental health status were more likely to receive combined treatment 
than individuals reporting excellent/ very good mental health status (AOR= 4.19, 
95% CI= 1.59, 11.05). Those with anxiety were significantly more likely to receive 
combined treatment (AOR= 3.21, 95% CI= 1.62, 6.37). cOnclusiOns: Future stud-
ies need to identify the barriers to combined treatment of depression with psy-
chotherapy and antidepressants among various subgroups of individuals with 
co-occurring COPD and depression.
PMH7
anTIPsycHoTIcs For TreaTMenT oF PedIaTrIc scHIzoPHrenIa: a 
sysTeMaTIc revIeW and neTWork MeTa-analysIs oF syMPToM 
conTrol, WeIgHT gaIn and dIsconTInuaTIon due To adverse evenTs
Harvey R.C.1, Shields G.E.1, James A.C.2
1BresMed, Sheffield, UK, 2Oxford Health, Oxford, UK
Objectives: Few studies discuss the effectiveness and side effects of the use of 
antipsychotics in the pediatric population, despite the poor prognosis associated 
with the disorder, including high suicide risk. This study explores the efficacy of 
trialled antipsychotics for early-onset schizophrenia in order to determine which 
treatments are potentially efficacious in this population. MethOds: A systematic 
literature review was performed to identify trials conducted in children and ado-
lescents with schizophrenia that reported symptom control (efficacy) using the 
positive and negative syndrome scale (PANSS), a medical scale frequently used 
for assessing the schizophrenia symptom severity in trials. A Bayesian random 
effects network-meta-analysis was performed, synthesizing data for relevant out-
comes, including mean change from baseline in PANSS scores (including positive 
and negative subscales), weight gain and treatment discontinuation due to adverse 
events. Results: Eleven studies were identified in the systematic review, and ten 
were included in the network meta-analysis. All treatments showed a greater reduc-
tion in PANSS scores at 6 weeks vs placebo; however, not all results were statisti-
cally significant. Haloperidol had the greatest reduction vs placebo; and treatment 
ranking probabilities suggested that haloperidol had the highest probability of being 
the best treatment in the network for reducing total PANSS scores. All treatments 
showed a trend of greater odds of discontinuing treatment due to adverse events vs 
placebo. However, pairwise comparisons were statistically non-significant. Nine out 
of thirteen treatments showed a trend of increased weight compared with placebo, 
